How to Start and Escalate Lemborexant for Adult Insomnia
How should clinicians use this article's indirect evidence when deciding whether to start lemborexant at 5 mg and when to consider increasing to 10 mg for adult insomnia?
When choosing lemborexant, clinicians still need to balance greater efficacy at 10 mg against a higher likelihood of somnolence. This guide applies to adults with insomnia for whom lemborexant is being considered and uses the article's dose-specific findings to structure that decision.
-
Start with the lower approved dose when initiating lemborexant
The article notes that the prescribing information recommends a lemborexant dose of 5 mg, to be increased up to 10 mg based on clinical response and tolerability. Use that lower starting dose as the default framework when beginning treatment, particularly if tolerability is a major concern.
-
Assess whether the treatment goal is strong symptom gain or lower sedation risk
Clarify whether the main goal is maximizing improvement in subjective sleep time and insomnia symptoms or minimizing somnolence. This matters because the article found a dose-response signal favoring 10 mg for efficacy on sTST but also a dose-response signal for somnolence.
-
Use dose-specific efficacy data to justify escalation
Consider moving from 5 mg to 10 mg when the patient needs greater subjective sleep benefit and 5 mg is insufficient. For sTST improvement greater than 80 minutes from baseline at month 1, the NNT versus placebo was 7 with lemborexant 10 mg and 13 with lemborexant 5 mg, and the NNT for 10 mg versus 5 mg was 14 with a 95% CI of 8 to 51.
-
Check the somnolence tradeoff before increasing the dose
Balance the possible efficacy gain against the higher likelihood of somnolence at 10 mg. At month 1, the NNH for somnolence was 15 with lemborexant 10 mg and 28 with lemborexant 5 mg, suggesting more somnolence with the higher dose; at month 3, somnolence remained among the lowest NNH values reported for pooled lemborexant doses.
-
Do not equate somnolence with frequent treatment stopping
If you escalate because benefit is insufficient, note that discontinuation due to adverse events remained uncommon in the article's analyses. Through month 1, discontinuation due to any adverse event, including somnolence, had NNH values of about 100 or higher regardless of dose and was not statistically significant.
-
Reassess benefit-risk over the first 1 to 3 months
Use early follow-up to decide whether the current dose is delivering enough benefit for the observed tolerability. The article reported that efficacy estimates in SUNRISE 2 were generally more robust at month 3 than month 1 for ISI outcomes, while month 3 pooled NNH values for lemborexant remained acceptable overall but were still lowest for somnolence and fatigue.
Clinical Considerations
- The clearer dose-response signal in this analysis was for sTST and somnolence, not uniformly for every efficacy or safety outcome.
- The article's conclusions about dose are drawn from indirect analyses of trial data rather than a dedicated flexible-dose titration protocol.
- Objective PSG outcomes for lemborexant were available only in SUNRISE 1, which enrolled older adults, limiting generalization of some short-term findings.
- The article does not provide a patient-level algorithm for exactly when to escalate; dose decisions should therefore stay tied to observed clinical response and tolerability.
Bottom Line
Start lemborexant at 5 mg and consider 10 mg only when additional benefit is needed and the patient can accept a higher likelihood of somnolence.
